Efficient production process for adeno-associated viral vectors
sponsored by Cytiva
November 12, 2020 at 17:00 UK
Speaker: Dr. Mats Lundgren
The use of adenovirus-associated virus (AAV) vectors in gene therapy is growing. To manufacture safe and efficacious clinical-grade virus, scalable and cost-effective production processes are needed. Here we present an efficient process for AAV production in suspension cell culture to purified bulk product. Each process step was evaluated and optimized. Cell culture conditions and triple-plasmid transfection were optimized for transfection efficiency and AAV2 production. Purification based on filtration and chromatography was developed. Options were compared for the affinity and ion exchange-based purification steps. Finally, a new analytical SPR-based assay was developed to quantitate AAV.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine